14 cases of Legionnaires’ disease reported in Florida, may be linked to gym
(NEW YORK) — At least 14 cases of Legionnaires’ disease have been reported in central Florida.
In an email to state Sen. Carlos Guillermo Smith, the Florida Department of Health revealed the outbreak is linked to a gym, reported ABC News affiliate WFTV.
The letter from the department did not list the name of the gym, but WFTV reported that a Crunch Fitness in Ocoee — 12 miles west of Orlando — had members reporting cases of Legionnaires’ disease.
Crunch Fitness told the station it is working with the health department, has closed off parts of the gym and is testing its pool and spa systems “out of an abundance of caution.”
Neither the Florida Department of Health nor Crunch Fitness immediately returned ABC News’ request for comment.
Legionnaires’ disease is a severe form of pneumonia caused by inhaling the Legionella bacteria in small droplets of water mixed in the air or contaminated water accidentally going into your lungs.
Legionella bacteria are found naturally in freshwater but typically grow best in warm water and in warm to hot temperatures, according to the Centers for Disease Control and Prevention (CDC).
The disease does not spread from person to person, but outbreaks can grow if the bacteria get into a building’s water supply, including in shower heads, sink faucets, hot water tanks, heaters and other plumbing systems.
Legionnaires has increased in prevalence over the last decade, reaching a peak of 2.71 cases per 100,000 in 2018, the CDC said. Cases dropped during the first year of the COVID-19 pandemic and then rebounded in 2021.
Although most people recover from Legionnaires’ disease with antibiotics, certain patients — including those who are immunocompromised or who suffer from chronic lung diseases — can develop complications that can be fatal.
About one out of every 10 people who develops Legionnaires’ disease will die due to complications, according to the CDC. Among those who develop Legionnaires’ disease during a stay in a health care facility, about one out of every four people will die, the federal health agency added.
A sign for the U.S. Food and Drug Administration’s White Oak campus in Silver Spring, Maryland is seen on April 8, 2025. Maansi Srivastava/For The Washington Post via Getty Images
(NEW YORK) — The Food and Drug Administration said Monday it will remove the “black box” warning from hormone replacement therapy (HRT) products for menopause.
The change comes after two studies in the early 2000s claimed that there were major risks associated with HRT, including breast cancer. This led to the FDA placing its highest warning label on the drugs, prompting a significant decline in usage.
The public health agency estimates millions of women have avoided HRT out of fear of cancer or heart risks, based on an outdated analysis of data.
“This is, in my opinion, one of the greatest mistakes in modern medicine — the demonization of hormone replacement therapy,” FDA Commissioner Dr. Marty Makary said on Monday.
An expert panel formed at the FDA in recent months reviewed the latest scientific studies and recommended the removal of the warning, Makary explained.
“Hormone replacement therapy may improve the health outcomes of women at a population level more than any other intervention, arguably, with the exception of, say, antibiotics or vaccines,” Makary said.
The timing of when women initiate HRT “is an important nuance that has been lost” and “one of the design flaws” of the early 2000s studies Makary said.
Current understanding is that the benefits of HRT outweigh the potential risks when taken before age 60 or within 10 years of the onset of menopause.
“This is really the result of doctors waving a flag in the air for decades of women who have said, ‘Hey, we didn’t feel like we got the right information,'” Makary said.
Consumers will see a different label on the products in several months, he added.
There are still risks associated with HRT and women considering it should speak with their doctor as it requires a prescription.
This is a developing story. Please check back for updates.
(NEW YORK) — Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added health benefits, early trial results suggest.
The pharmaceutical company presented the results for its newer drug at the annual ObesityWeek conference on Thursday.
Known as amylin analogs, these drugs slow digestion and curb appetite, similar to the more well-known GLP-1 drugs, but act through a different hormone.
Amylin is a hormone that is co-secreted with insulin through the pancreas and helps regulate blood glucose levels, appetite and gastric emptying, which is the process of food moving from the stomach to the intestines.
These drugs can treat type 2 diabetes and obesity by imitating the body’s natural amylin.
While the effects are similar to Eli Lilly’s GLP-1 drugs, Mounjaro and Zepbound, some studies have suggested that amylin analogs may lead to a lower loss of lean muscle mess relative to fat mass.
Early trial results of Eli Lilly’s amylin analog, known as eloralintide, helped patients who were overweight or obese — with at least one pre-existing condition related to obesity and without type 2 diabetes — lose 9.5% to 20.1% of their body weight.
This was compared to patients who lost 0.4% when taking a placebo, according to the trial results, which were published in the medical journal The Lancet.
Patients who were treated with eloralintide also saw improvements in blood pressure, fat levels in the blood stream and markers of inflammation.
Eli Lilly said it will begin phase 3 clinical trials after the promising results, with the aim to enroll patients by the end of the year.
“Obesity is a complex condition, and no single treatment works for everyone. To truly address each patient’s needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them,” Dr. Liana K. Billings, lead author of the study and director of clinical and genetics research in diabetes and cardiometabolic disease at Endeavor Health in Skokie, Illinois, said in a statement.
She added that the early trial results underscore “the potential of amylin receptor agonists to expand our therapeutic strategies and better serve individuals living with obesity.”
Eli Lilly is not the only drug company testing amylin analogs. Novo Nordisk’s version, called cagrilintide, led to about a 12% weight loss over 68 weeks in early, previously published studies.
Novo is testing a combination of cagrilintide and semaglutide — the latter of which is known under the brand name Wegovy — that produced about a 22% weight loss in people with obesity but not diabetesin a previously published, late-stage clinical trial.
(NEW YORK) — As measles continues to spread across the United States, questions have emerged about whether the country will retain its measles elimination status.
The U.S. is currently experiencing the highest number of measles cases reported in more than three decades, in large part due to an outbreak in western Texas that infected more than 700 people and spread to New Mexico and Oklahoma.
Meanwhile, an outbreak in Arizona and Utah currently shows no signs of slowing down and a separate outbreak in South Carolina has sent dozens of students into quarantine.
If spread of the virus continues into late January, it will mean the U.S. has seen a year of continuous transmission, which could lead to a loss of the country’s elimination status. Measles would once again be considered endemic or constantly circulating.
The threat of the U.S. losing its elimination status is looming after Canada lost its measles elimination status following a struggle to contain a year-long measles outbreak, public health experts told ABC News.
“I do think that the likelihood that we’re going to lose status, especially if things continue the way that they’re going, is I think pretty high,” Dr. Tony Moody, a professor of pediatrics in the division of infectious diseases at Duke University Medical Center, told ABC News.
State of measles in the U.S.
As of Wednesday, there have been 1,753 confirmed cases across 42 states this year, according to the Centers for Disease Control and Prevention (CDC).
There have been 45 outbreaks, so far this year compared to 16 outbreaks all last year, CDC data shows.
Additionally, 92% of cases have been among those who are unvaccinated or whose vaccination status is unknown, according to the CDC.
There have been three measles deaths this year — the first fatalities due to the disease in a decade — including among two unvaccinated school-aged children in Texas and one unvaccinated adult in New Mexico.
The CDC currently recommends that people receive two doses of the measles, mumps, rubella (MMR) vaccine, the first at ages 12 to 15 months and the second between 4 and 6 years old. One dose is 93% effective, and two doses are 97% effective against measles, the CDC says.
However, CDC data shows vaccination rates have been lagging in recent years. During the 2024-25 school year, 92.5% of kindergartners received the MMR vaccine. This is lower than the 92.7% seen the previous school year and the 95.2% seen in the 2019-20 school year, prior to the COVID-19 pandemic.
Even in states with high MMR vaccine uptake, pockets of unvaccinated or under-vaccinated communities can lead to rapid spread.
For example, in Texas, 94.3% of kindergartners were up to date on their MMR vaccine for the 2023-24 school year, CDC data shows. However, in Gaines County — the epicenter of this year’s outbreak — 17.6% of kindergartners were exempt from at least one vaccine during the 2023-24 school year, one of the highest exemption rates in the state, according to state health data.
“It’s kind of like you have a very dry forest, so any spark that comes in can burn down the entire forest,” Dr. Peter Chin-Hong, a professor of medicine and infectious diseases specialist at the University of California, San Francisco, told ABC News. “That’s what’s happening, which is fewer people being vaccinated, as evidenced by the drop in in people entering kindergarten.”
He said one case of measles is like a spark that quickly turns into a blaze as it spread through an unvaccinated community “and that’s why it’s hard to put out the fire.”
How loss of status is determined
The loss of status is determined by the Pan American Health Organization (PAHO, an agency of the U.N. that oversees international health in the Americas.
An independent body of experts established by the PAHO — known as the Measles, Rubella, and Congenital Rubella Syndrome Elimination Regional Monitoring and Re-Verification Commission (RVC) — meets at least once a year to monitor and re-verify measles and rubella elimination among countries in the Americas.
A person familiar with how PAHO determines loss of elimination status told ABC News that there would have to be compelling evidence that there has been continuous spread of measles in the U.S. since January, when the first cases were reported in Texas and that other outbreaks may trace back to the Texas outbreak.
The person said the committee will get together in mid-2026 to look at the data, write its next report and formally submit it to the PAHO for review. The annual meeting will likely take place in late 2026, unless a previously unplanned meeting is convened beforehand.
“The RVC holds annual meetings with all member states, conducts visits to priority countries, reviews national sustainability reports, and issues recommendations to the Director of PAHO,” a spokesperson for PAHO told ABC News. “It may also convene extraordinary meetings with member states to provide recommendations on specific topics or to follow up on outbreak situations. At this time, no extraordinary meeting has been scheduled for next year specifically to assess the U.S. or Mexico situation, but such a meeting could be convened if the epidemiological situation warrants.”
Between April 2025 and October 2025, Mexico has seen 4,550 cases, according to the WHO, which could also lead to the loss of its elimination status.
Moody explained that the U.S. having measles elimination status, which it received in 2000, is less of a formal declaration and more of a statement that a county has a relatively low number of cases and no sustained transmission.
Loss of status would similarly be a statement that a country has sustained transmission and that the virus is constantly present, he said.
“What does it mean from a public health perspective, or a parent’s perspective, it means that we have a higher risk for seeing transmission, and that if someone goes to a place where there is sustained transmission, there’s kind of an increased risk and, truthfully, you can pick it up just about anywhere,” Moody said.
Canada’s loss of elimination status
Earlier this month, the Public Health Agency of Canada said it was informed of the elimination status loss by PAHO after more than 12 months of continuous measles transmission. Canada’s outbreak began in late October 2024, and the county has seen more than 5,200 confirmed and probable cases since then, data from the health agency shows.
As a result, the Americas region lost elimination status as well.
Canada can re-establish its measles elimination status if measles transmission related to the current outbreak is “interrupted” for at least 12 months, according to the county’s health officials.
“Given that we share one of the longest borders in the world with Canada. It’s not as if there’s some magic barrier between U.S. and Canada,” Moody said. “If there’s transmission in Canada, we’re going to get it in the United States. … I’m not saying that Canada has put us at risk. We’ve kind of put ourselves at risk but … I do see it as being a highly likely thing that we’re going to see continued transmission.”
Canada will present and implement an action plan under PAHO’s regional framework to increase immunization coverage, reinforce surveillance systems and ensure rapid outbreak response to stop spread. This shows what the U.S. would likely experience if it lost its status.
“If we lose our status, it’ll be hard to regain it,” Chin-Hong said, noting how many workers have been laid off at HHS that might have helped control large outbreaks. “Not only loss of expertise, but just loss of the workforce in general, the people who go out and do the surveillance and contain the epidemic by vaccination efforts and all that. … It just denotes how fragile public health gains are. In general, it’s easy to lose it and hard to get it back.”
How to prevent further spread
Public health experts told ABC News there are several steps that can be taken to help control the spread of measles in the U.S. including increasing funding to public health for monitoring and surveillance as well as spreading awareness about how dangerous measles can be.
However, they add that the best way to stop the spread is through vaccination, both to protect yourself and the most vulnerable individuals.
“We can’t control the people who are unable to get vaccines because they’re being treated for cancer, because they are born with an immunodeficiency,” Dr. Aaron Milstone, pediatric director of infection prevention at Johns Hopkins Health System, told ABC News. “What we can control is everyone else in the community who is eligible for a vaccine, who does not take it, and that’s the reason that measles is spreading, in part, because the herd protection from our community has gone down.”
As an extra step, public health agencies have previously recommended early MMR vaccination for infants living in outbreak areas or traveling internationally.
This would result in three doses overall: an early dose between age 6 months and 11 months and then the two regularly scheduled doses at age 1 and between ages 4 and 6.
Milstone said the recommendation to give a child their first MMR dose at age one was under the assumption that they likely would not be exposed to measles before then and that antibodies passed in utero would help protect them during their first year of life.
Now, with the continuous spread being seen, “are we going to have to rethink our recommendations for when to vaccinate kids in the U.S.?” Milstone said.
